Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

Affiliations

• ¹ Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
• ² GlaxoSmithKline, Collegeville, PA, USA.
• ³ Medimmune, Gaithersburg, MD, USA. adamsla@medimmune.com.
• ⁴ Oncology Research and Development, GlaxoSmithKline, Research Triangle Park, Durham, NC, USA. adamsla@medimmune.com.
• ⁵ Janssen Research & Development, Spring House, PA, USA.
• ⁶ Oncology Research and Development, GlaxoSmithKline, Research Triangle Park, Durham, NC, USA.
• ⁷ CSL Behring, King of Prussia, PA, USA.
• ⁸ Astex Pharmaceuticals, Inc., Pleasanton, CA, USA.
• ⁹ Exelixis, South San Francisco, CA, USA.
• ¹⁰ Genentech, San Francisco, CA, USA.
• ¹¹ Biomarker, Translational & Predictive Medicine Consulting, San Francisco, CA, USA.
• ¹² University of Chicago, Chicago, IL, USA.
• ¹³ Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Collegeville, PA, USA.
• ¹⁴ NantOmics, LLC, Rockville, MD, USA.
• ¹⁵ Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
• ¹⁶ Yale Cancer Center, New Haven, CT, USA.
• ¹⁷ Barbara Ann Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.